Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Teratogenicity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Teratogenicity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-003792-34 Sponsor Protocol Number: DIA-2-REDESIGN Start Date*: 2015-03-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: RANDOMIZED DOUBLE BLIND PARALLEL DESIGN STUDY COMPARING RISK OF NOCTURNAL HYPOGLYCEMIA AND CRITICAL ARRHYTHMIAS WITH SITAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY C...
    Medical condition: Patients with diabetes mellitus type 2 inadequately controlled on metformin monotherapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004287-56 Sponsor Protocol Number: CHUBX2016/44 Start Date*: 2019-11-21
    Sponsor Name:CHU de Bordeaux
    Full Title: Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study
    Medical condition: rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012151-23 Sponsor Protocol Number: SPON 671-09 Start Date*: 2009-11-11
    Sponsor Name:Cardiff University
    Full Title: A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer ...
    Medical condition: Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003119-13 Sponsor Protocol Number: 14/0172 Start Date*: 2015-02-11
    Sponsor Name:Joint Research Office- UCL
    Full Title: Can simvastatin significantly reduce the amount of immunosuppressive medication required by patients with sight threatening uveitis? A phase IIb, single site, randomized, placebo controlled, double...
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    19.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006187-47 Sponsor Protocol Number: AI424-494 Start Date*: 2012-11-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000786-24 Sponsor Protocol Number: NET-2013-02355002 Start Date*: 2017-03-07
    Sponsor Name:IRCCS Burlo Garofolo
    Full Title: Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001642-17 Sponsor Protocol Number: AMB116457 Start Date*: 2013-04-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021572-29 Sponsor Protocol Number: AMB114588 Start Date*: 2010-11-23
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    12.1 10065150 Associated with pulmonary arterial hypertension LLT
    12.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    12.1 10065152 Familial pulmonary arterial hypertension LLT
    12.1 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Completed) NL (Ongoing) ES (Completed) HU (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006719-21 Sponsor Protocol Number: IMCL CP13-0707 Start Date*: 2008-08-07
    Sponsor Name:ImClone LLC
    Full Title: A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET
    Medical condition: Previously-treated, advanced or metastatic soft tissue and Ewing’s sarcoma/peripheral primitive neuroectodermal tumor (PNET)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015562 Ewing's sarcoma metastatic LLT
    9.1 10035639 PNET of bone metastatic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000850-48 Sponsor Protocol Number: CA184-156 Start Date*: 2012-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease ...
    Medical condition: Extensive Stage Disease Small Cell Lung Cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) IT (Completed) SE (Completed) DE (Completed) CZ (Completed) AT (Completed) GB (Completed) PT (Completed) HU (Completed) ES (Completed) NL (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002018-29 Sponsor Protocol Number: A3921165 Start Date*: 2020-12-09
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Ongoing) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009035-30 Sponsor Protocol Number: CP15-0802 Start Date*: 2009-10-27
    Sponsor Name:ImClone LLC
    Full Title: Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refrac...
    Medical condition: Platinium-refractory or Platinium-resistant Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001356-10 Sponsor Protocol Number: Revail Start Date*: 2012-01-12
    Sponsor Name:LYSARC
    Full Title: STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA ...
    Medical condition: Angioimmunoblastic T-cell Lymphoma (AITL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001883-12 Sponsor Protocol Number: GI1616 Start Date*: 2016-09-14
    Sponsor Name:Herlev & Gentofte Hospital, Oncology Dept.
    Full Title: A PROSPECTIVE RANDOMIZED, OPEN-LABEL PHASE 2 STUDY OF IMMUNE CHECKPOINT INHIBITION, NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN COMBINATION WITH RADIATION THERAPY IN PRETREATED PATIENTS WITH METASTATIC...
    Medical condition: Patients with metastatic pancreatic cancer or metastatic biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003759-13 Sponsor Protocol Number: GI1931 Start Date*: 2019-12-20
    Sponsor Name:Department of Oncology, Herlev & Gentofte
    Full Title: Phase 1/2 study in borderline resectable, locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and ...
    Medical condition: Locally advanced pancreatic cancer, non-resectable or borderline resectable, or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004792-30 Sponsor Protocol Number: HE316 Start Date*: 2018-10-03
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004531-23 Sponsor Protocol Number: CV181-206 Start Date*: 2013-07-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult...
    Medical condition: Type 2 Diabetes.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019547-19 Sponsor Protocol Number: AMB112529 Start Date*: 2010-07-16
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    12.1 10065150 Associated with pulmonary arterial hypertension LLT
    12.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    12.1 10065152 Familial pulmonary arterial hypertension LLT
    12.1 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) NL (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000508-24 Sponsor Protocol Number: 7406 Start Date*: 2015-06-12
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust
    Full Title: A Feasibility Study of Bezafibrate in Mitochondrial Myopathy
    Medical condition: Mitochondrial myopathy due to mt.3243A>G mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004438-40 Sponsor Protocol Number: GI1950 Start Date*: 2020-04-06
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation.
    Medical condition: Pretreated patients with advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA